Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In addition to developing on its own, myelofibrosis may also develop as a result of ET or PMF.
Myeloproliferative neoplasms are most common in older adults. Out of every 100,000 people in the United States, an estimated 44 to 57 people have PV, and a similar number have ET. Myelofibrosis is less common, affecting 4 to 6 people per 100,000.
An important advance in our understanding of MPN is the identification of certain gene mutations that contribute to these conditions. In the case of myelofibrosis, this discovery has contributed to the development of new drugs to treat the condition. The last year marked important progress in the management of PV and myelofibrosis with a new treatment option now available for PV patients.
CancerConnect News coverage of advances in the management of MPNs included the following key developments:
2014 Ask the MPN Expert
- Ask the Expert: Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis
- New Gene Mutation Identified in Myeloproliferative Neoplasms
2014 Research and FDA News in Polycythemia Vera
- Jakafi: First Drug Approved for Treatment of Polycythemia Vera
- FDA Accepts Supplemental New Drug Application for Jakafi and Priority Review Granted for the Treatment of Polycythemia Vera
- Jakafi® Improves Symptoms and Quality of Life in Polycythemia Vera
- Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera
- Switching from Best Available Therapy to Jakafi® Improves Outcomes in Polycythemia Vera
- Jakafi Improves Hematocrit Control and Reduces Spleen Volume in Polycythemia Vera Patients
2014 Research News in Myelofibrosis
- Protein Inhibitor INCB039110 Appears Active in Myelofibrosis
- Myeloproliferative Neoplasms: When Good Cells Go Bad
- Your Questions Answered: Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis
- Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information
- Jakafi Safe and Effective in Polycythemia Vera
- Jakafi Continues to Benefit Patients with Myelofibrosis
- Jakafi Prolongs Survival in Primary Myelofibrosis
2014 Research News in Essential Thrombocythemia
Stay up to date on MPN research news and connect with others affected by polycythemia vera, myelofiboriss and essential thrombocythemia in the CancerConnect online MPN community here.
Copyright © 2015 CancerConsultants. All Rights Reserved.